Recent studies have reported that CRISPR-Cas9 gene editing may bear cancer risk due to a selection against cells with a functional p53. Here, analyzing genome-wide CRISPR and RNAi screens we systematically chart the p53-related oncogenic risk of individual CRISPR knockouts and find supporting evidence in patients' tumors. Importantly, we find that CRISPR knockouts may select for mutated variants of the cancer drivers VHL and KRAS, comparable to that of p53.
performed in a small number of primary cell lines, calling for a broader and more comprehensive evaluation.
To expand the scope of this prior work we harnessed the power of data from genomewide gene essentiality screens conducted in a large panel of cancer cell lines from different tissues of origin and with a variable p53 status [5, 11] . Our key idea was to search for individual genes whose silencing results in significantly higher viability (reduced essentiality) in p53 mutated vs p53 wild-type (WT) cell lines, as this testifies for genes whose knockout (KO) can lead to the selection of p53 mutated cells. Importantly, we searched for genes that showed this effect only in the CRISPR-KO screens and not in shRNA gene knockdown (KD) screens. The latter serve as controls in the context of our effort that is focused on identifying the CRISPRspecific effects.
Analyzing the CRISPR essentiality data of the 248 cell-lines shared in both CRISPR and shRNA screens, we find 981 genes whose KO results in significantly higher cell viability in p53 mutated (N=173) vs p53 WT cell lines (N=75), while only 237 genes show the opposite trend (i.e. with significantly lower post-KO viability in p53 mutant cell lines, Methods). In contrast, the respective gene numbers related to p53 status were more balanced in the shRNA screens (~1500 each) (chi-squared test P<1.4E-284; the results are controlled for gene copy number as a potential confounding factor, Methods, Figure 1a, top panel) . These differences are visualized in Figure 1a (lower panel) , which plots the median post-KO/KD cell viability values in p53 mutant vs WT cell lines, underscoring the increased viability of mutated p53 cells after their KO (Kolmogorov-Smirnov P=1.3E-282). We repeated the analysis above focusing strictly on cell lines harboring known loss-of-function p53 mutations (Methods, N=78), using the same WT cell-lines as controls (N=75), observing an even higher significance in the differences of median post-KO/KD cell viability (chi-squared test P=1.7E-292, Table S2 , see Methods). These findings were further corroborated by a permutation test where the cell line's p53 mutation status was shuffled 10,000 times (P<1E-4, Methods). Collectively, our results confirm and expand the findings of [9, 10] . Reassuringly, the genes we identified with higher post-CRISPR-KO viability in p53 mutated cell lines significantly overlap with those showing a similar effect in the CRISPR-KO screens performed in [10] (hypergeometric test P<0.03, Supplementary notes).
Among the 981 genes whose CRISPR-KO results in higher cell viability when p53 is mutated, 861 genes show this trend only in the CRISPR screens and not in the shRNA screens, and thus are termed CRISPR-specific differentially essential positive (CDE+) genes. Importantly, the mutational status of p53 is significantly associated with the essentiality of CDE+ genes independent of copy number (Figure S1). One example of the most significant CDE+ gene, TAF8, is presented in Figure 1b . Notably, the CDE+ genes are enriched for pathways including homology-directed repair and the Fanconi anemia (FA) pathway (both with FDR-corrected hypergeometric P<0.03, Table S1 ), in accordance with the recent finding that FA genes are specifically involved in DSB repair during CRISPR-KO [13] . Furthermore, the CDE+ genes are preferentially located in chromosomal bands containing common fragile sites (CFSs) (hypergeometric P=2E-4, Figure 1c , Table S3 ), which are prone to replicative stress, fork collapse and DNA breaks that may cause genomic instability [14] (notably, this is CRISPRspecific as it not observed for the genes showing differential essentiality with regard to p53 mutation status in the shRNA screens). As CRISPR-KO events can induce kilobase-scale structural alterations near the targeted site [15] , it is possible that the formation of a CRISPRinduced DSBs in the vicinity of CFS-associated replicative intermediate can lead to excessive stress on the system promoting the activation of a p53-dependent cell death response. Such a phenomenon could underlie the selection pressure for p53 inactivation and the apparent higher essentiality in p53 WT vs p53 mutated cell lines and is consistent with homology-directed repair events participating in the CRISPR-specific response. Figure 1d shows the median differences of post-KO viability between p53 mutant vs p53 WT cell lines for each CDE+ gene, which we term its CRISPR-KO risk, and the top hits are marked, including genes located in CFSs and involved in DNA repair (Methods). As evident, the magnitude of the differential viability scores observed for top ranked CDE+ genes is high, at a level that is likely to result in a widely enriched p53 mutated cell population after just a few cell generations starting from a heterogeneous population of mutated and WT cells.
In the inverse direction, 237 genes are more essential in CRISPR screens in p53 mutated than WT cell lines. Among those, 185 genes show this trend only in the CRISPR screen and not in the shRNA screen, termed CRISPR-specific differentially essential negative (CDE-) genes.
CDE-genes are enriched for pathways related to mitotic checkpoints, DNA replication and cell cycle regulation, cellular processes that frequently engage p53 (Table S1, Figure 1e , FDR corrected hypergeometric P<0.1; these enrichments are CRISPR-specific as differentially essential genes in the shRNA screens are not significantly enriched for these pathways). In accordance with the findings of [9, 10] , the top ranked CDE-gene is CDKN1A (a.k.a. p21, Wilcoxon rank sum P<1.85E-08, Figure 1d To gain further insights into the genes and pathways that are specifically involved in response to CRISPR-KO vs those involved in response to shRNA-KD, we analyzed the LINCS l1000 [16] data, where expression was measured before and after CRISPR-KO and shRNA-KD screens across 53 genes in six cell lines. We identified a CRISPR-specific consensus differential expression signature (CDES), comprised of genes that are most frequently differentially expressed specifically following CRISPR-KO but not shRNA-KD (Methods). The top pathways that CDES genes are enriched for include cell cycle, mitotic M/G1 phases and G2-M checkpoints (all with FDR-corrected Kolmogorov-Smirnov P<0.025, see Methods, Table S4 ), consistent with the previous findings that cell cycle arrest is triggered in response to CRISPR mediated DNA damage [10] .
Our analysis in cancer cell lines has shown that CDE+ genes of p53 are (i) enriched for homology-directed DNA repair (a.k.a., homologous recombination) and FA pathway, and (ii) preferentially located on CFSs in the genome, two elements that can play a role in gene copy number variation. Given that the CRISPR-KOs of CDE+ genes preferentially reduce the viability of p53 WT cells, we hypothesized that copy number alterations in CDE+ genes will analogously reduce the fitness of p53 WT tumors. To test this hypothesis, we analyzed the somatic copy number alteration (SCNA) and patient survival data of 7,547 samples from the cancer genome atlas (TCGA) [17] . As control, we used genes whose essentiality is not associated with p53 mutational status. We find that the SCNA (both amplifications and deletions, Methods) in CDE+ genes is significantly lower in p53 WT tumors compared to that of control genes (Wilcoxon rank sum P<2.7E-5), suggesting that copy number variations in CDE+ genes are selected against specifically in p53 WT tumors, as p53-mediated responses are detrimental. As further controls, this is not the case for p53 mutant tumors or for CDE-genes (Wilcoxon rank sum P>0.5). In addition, we observe that the magnitude of SCNA events of CDE+ genes is associated with enhanced patient survival specifically in p53 WT tumors and not in p53 mutated tumors (hypergeometric P<0.046, Methods), further testifying that these amplification/deletion events reduce the fitness of these WT tumors. Taken together, these observations suggest that the CRISPR risks of CDE+ genes identified in vitro may also influence the evolution of patients' tumors.
To identify additional cancer drivers like p53, whose mutational status impacts CRISPR-KO outcome in a differential and specific manner, we applied the analysis described above to each gene in the list of cancer driver genes provided by Vogelstein et al. [18] (focusing on those genes that are mutated in at least 10 of the screened cell lines (N=61)). We identified the tumor suppressor VHL (Von Hippel-Lindau) and the oncogene KRAS as such master CDE regulators (or "master regulators" for short, Methods, Figure 2a , Table S7 ). That is, like p53, each of these two genes have a CDE+/-skewed distribution in the CRISPR compared to the shRNA screens.
The CDE+ and CDE-genes of each of these master regulators are listed in Table S1 . Some genes are classified as CDE+ of multiple master regulators, and thus their CRISPR-KO may impose considerable risk of selecting for more than one mutated cancer gene: SREK1 is both a p53 and VHL CDE+ gene; fourteen genes are CDE+ genes of both KRAS and p53; and ten genes are CDE+ genes of both the KRAS and VHL ( Table S6) .
As evident from Figure 2b , the two additional master regulators uncovered by our analysis have considerably higher median risk levels than p53 (that is, the CRISPR-KO of their CDE+ genes is likely to drive higher levels of selection than KO of the CDE+ genes of p53).
Notably, for VHL, although the absolute number of its CDE+ genes is smaller than that of p53, the ratio of its CDE+ to CDE-genes is strikingly higher than that observed for p53, while the parallel distribution observed in the shRNA-KD screens is balanced (Figure 2c ). Just like p53 the mutational status of VHL is significantly associated with the essentiality of CDE+ genes independent of copy number (Figure 2d) . Notably, CDE+ genes of VHL are also enriched in chromosomal bands of CFSs (Figure 2e and Table S3 , hypergeometric P=0.024). Indeed, VHL can act as a positive regulator of p53 in DNA damage-induced cell cycle arrest or apoptosis [19] , possibly accounting for its role as a master regulator.
For KRAS, a major oncogene that is involved in cell signaling, we find high numbers of CDE genes, while only very few KRAS mutation-associated genes are identified in the shRNA-KD screens (Figure 2c ). Indeed, most of its mutations in the cell-line collection we studied are missense hotspot mutations, suggestive of gain of function. Mutated KRAS is known to activate various DNA repair pathways and may override the trigger of cell death upon DNA damage [20, 21] , supporting its role as a master regulator. Consistently, the CDE-genes of KRAS are significantly enriched for cell cycle checkpoints and DNA DSB repair pathways (FDR-corrected Kolmogorov-Smirnov P<0.05, Methods, Figure 2f , Table S1 ). As observed for VHL and p53 (Figure 2d and S1, respectively), the effects of KRAS are also independent of gene copy number ( Figure S1) . Reassuringly, mining the data from CRISPR and shRNA screens performed in the same isogenic KRAS-mutated cell line [22] , the inferred KRAS CDE-genes significantly overlap with the differentially essential genes identified in the CRISPR (and not in the shRNA) screens (hypergeometric P<0.05, Methods). In sum, our results extend the scope of the previous findings in human primary cells [9, 10] to a genome-wide analysis of these effects across hundreds of cancer cell lines from diverse tissues of origin. By analyzing shRNA-KDs as controls, we could identify gene-KOs with truly CRISPR-specific selection effects (that is, those that occur only CRISPR and not in shRNA screens). Those include both the CDE+ genes whose KOs imposes oncogenic risk and CDEgenes whose KOs may counteract the latter. Despite the noisy nature of pooled CRISPR/RNAi screens [23] , our results support the earlier findings that the selection of mutant p53 cells is mediated via cell-cycle regulation [9] . Beyond that, our findings also point to the role of DNA repair genes and their CFS locations. Our analysis is based on data from cancer cell lines, and yet shows a significant overlap with the findings in human non-cancerous cells reported earlier.
While the results obtained in cancer cell lines should obviously be interpreted with care, the heterogeneity and prevalence of mutations available in the latter expand our ability to detect the underlying associations. Indeed, going beyond p53, our analysis reveals two novel master CDE regulators, KRAS and VHL, suggesting that genomic editing by CRISPR-Cas9 may induce tumorigenic alterations in these important cancer driver genes as well. Interestingly, we find evidence that the CRISPR-related KO effects identified in vitro may have an echo that is traceable in vivo, modulating the evolution of patients' tumors. Our work demonstrates yet again how big data analysis may be employed to complement experimental screens and extend their findings.
Methods

CRISPR and shRNA essentiality screen data
We obtained CRISPR-Cas9 essentiality screen (or dependency profile) data in 436 cell lines from Meyers et al. [5] for 16,368 genes, whose expression, CNV and mutation data are available via CCLE portal [24] . We obtained the shRNA essentiality screen data in 501 cell-lines from DepMap portal [14] for 16,165 genes, whose expression, CNV and mutation data is available publically via CCLE portal [24] . The 248 cell-lines and 14,718 genes that appear in both datasets were used in this analysis (Table S5, S6) . For mutation data, only non-synonymous mutations were considered. Synonymous (silent) mutations were removed from the pre-processed MAF files downloaded from CCLE portal [24] .
Identifying CRISPR specific differentially essential genes of a master CDE regulator
For a given master CDE regulator (e.g. p53), we checked which gene's essentiality (viability after knockout) is significantly associated with the mutational status of the master regulator using a Wilcoxon rank sum test in the CRISPR and shRNA datasets, respectively (FDR<0.1). CRISPRspecific differentially essential (CDE) genes denotes two sets of genes depending on the direction of the association with the mutation. CDE+ genes are those whose CRISPR-KO is significantly more viable when the master regulator is mutated while their shRNA silencing is not, whereas CDE-genes are those whose CRISPR-KO is significantly more viable when the master regulator is WT while their shRNA silencing is not. We filtered out any candidate CDE genes whose copy number was also significantly associated with the given mutation to control for potentially spurious associations coming from copy number (we removed genes showing significant association (FDR<0.1)) -the exact procedure used is described below in the section titled "Identifying master CDE regulators of CRISPR-KO").
Identifying CDEs associated with p53-loss-of-function mutations
Out of a total of 248 cell lines that we analyzed, 173 cell lines (69.7%) have p53 nonsynonymous mutations. In addition to identifying CDEs by considering all non-synonymous mutation, we additionally employed a more conservative approach where we aimed to consider only p53 loss-of-function (LOF) mutations in the CDE identification process. To this end, we considered a mutation to be LOF if it was classified as non-sense, indel, frameshift, or among the 4 most frequent non-functional hotspot mutations (R248Q, R273H, R248W and R175H within the DNA-binding domain, determined as pathogenic by COSMIC [26] ). Using this definition we obtained new mutation profiles for p53 and identified CDE genes via the same method described in the section titled "Identifying CRISPR specific differentially essential genes of a master CDE regulator."
Identifying master CDE regulators of CRISPR-KO
To identify additional master regulators like p53, we considered 121 cancer driver genes identified by Vogelstein et al. [18] , whose nonsynonymous mutation is observed in at least 10 cell lines (N=61). We determined whether each of these genes is a master CDE regulator as follows:
for each of the 61 candidate genes, we tested the association between the essentiality of each of genes in the genome (reflected by post-KO cell viability) with the mutational status of the candidate master regulator gene using a Wilcoxon rank sum test. We then counted the number of genes, whose essentiality is: (i) significantly positively associated with the candidate master regulator mutational status (FDR-corrected p-value<0.1, median essentiality of WT>mutant of the cancer gene), (ii) significantly negatively associated with the candidate master regulator mutational status (FDR-corrected p-value<0.1, median essentiality of WT<mutant of the cancer gene), and (iii) not associated (FDR-corrected p-value>0.1) with the candidate master regulator mutation status; we performed this computation separately for the CRISPR and the shRNA screens, respectively. This computation results in a 3-by-2 contingency table for each candidate master regulator gene. We then checked whether the distribution of the above three counts in CRISPR dataset significantly deviates from that in shRNA dataset via a Fisher's exact test on the contingency table. If each of the values in the contingency table was greater than 30, we used the chi-squared approximation of the Fisher's exact test. We further filtered out any candidate CDE genes whose copy number was also significantly associated with the given mutation to control for potentially spurious associations coming from copy number (we removed genes showing significant association (FDR<0.1)). We performed this procedure for all 61 candidate genes one by one and selected those with FDR corrected Fisher's exact test <0.1. We further filtered out the candidate master regulators whose mutation profile is correlated with p53 mutation profile via a pairwise Fisher test of independence (FDR<0.1). We finally report the master regulators that have substantial number of CDE+ genes (N>300).
Pathway enrichment analysis of CDE+/CDE-genes
We analyzed the CDE+/CDE-genes of each of the master CDE regulators for their pathway enrichment with the pathway annotations from the Reactome database [25] in two different ways. First, we tested for significant overlap between our CDE genes with each of the pathways with hypergeometric test (FDR<0.1). We repeated the test for genes showing differential essentiality in the shRNA screens (shRNA-DE genes), and only reported those significant pathways specific to CDE genes but not shRNA-DE genes. Second, we ranked all the genes in the CRISPR-KO screen by the differences in their median post-KO cell viability values in mutant vs WT cells, and the standard GSEA method [27] was employed to test whether the genes of each Reactome pathway have significantly higher or lower ranks vs the rest of the genes (FDR<0.1). We repeated the GSEA analysis with the genes ranked by differential post-KD cell viability in the shRNA screen, and only reported significant pathways specific to CRISPR but not shRNA screen. We confirmed that for p53, the GSEA method was able to recover the top significant pathways identified by the hypergeometric test (e.g. those in Figure 1e ), although extra significant pathways were identified (Table S1), consistent with the higher sensitivity of the GSEA method [27] . For p53 and KRAS CDE-genes respectively, the enriched pathways were clustered based on the Jaccard index and the number of overlapping genes with Enrichment Map [28] , and the largest clusters were visualized as network diagrams with Cytoscape [29] .
To study the potential enrichment of CDE genes in common fragile sites (CFSs), we obtained the chromosomal band locations of CFSs from [14] , and we defined the CFS gene set as the set of all genes located within these chromosomal bands (obtained from Biomart [30] ). We tested for a significant overlap between our CDE genes and the CFS gene set with hypergeometric test, and also confirmed the lack of significant overlap with the corresponding shRNA-DE genesets.
Identification of CRISPR-specific consensus differential expression signature (CDES)
The Library of Integrated Network-Based Cellular Signatures (LINCS) l1000 Phase I and II datasets were obtained from the GEO database (GSE92742 and GSE70138). We selected the subset of level 5 data (computed gene expression signatures as z-scores based on the standard l1000 protocol) [16] for assays where both knockdown by RNA interference (RNAi) and knockout by CRISPR/Cas9 were performed for the same gene in the same cell line. This resulted in z-scores of expression level changes for 978 measured genes for perturbation of 53 genes in 6 cell lines. Consensus gene-level signatures were computed from shRNA or sgRNA-level signatures using the weighted-average method described in [23] . For each signature of gene perturbation in the same cell line, the RNAi z-scores were subtracted from the CRISPR z-scores as a way to obtain a gene signature specific to the CRISPR/Cas9 technology. The obtained CRISPR-specific signatures for each of 53 gene KO perturbations were then averaged (mean) to reduce gene-specific effect, resulting in a CRISPR-specific consensus differential expression signature (CDES) for each cell line that best represents the gene expression changes in response to the CRISPR/Cas9 technology specifically (i.e. Cas9-induced DNA breaks and related cellular events). A further CDES was also obtained by again averaging (mean) the CDES across the cell lines. The CDES's were then analyzed for functional enrichment of the top altered genes using the GSEA method [27] with the geneset annotation from Reactome [25] .
Enrichment of KRAS CDE-genes in the KRAS isogenic essentiality screens
To evaluate the relevance of our large-scale analysis in a single isogenic cell line, we analyzed the CRISPR-KO and shRNA-KD screen of 1,155 essential genes performed in KRAS mutated isogenic DLD1 cell line [22] . We first identified the differentially essential genes that show higher essentiality in KRAS mutant vs WT cells (top 40-percentile) for each of CRISPR and shRNA screens. We then determined a subset of genes that are specifically showing this trend in CRISPR screen, and checked whether this subset has significant overlap with our KRAS CDE-geneset using hypergeometric test.
Testing the clinical relevance of copy number alterations of CDE genes in p53 mutated vs WT tumors
Given that the CRISPR-KOs of CDE+ genes preferentially reduce the viability of p53 WT cells, we hypothesized that copy number alterations in CDE+ genes will analogously reduce the fitness of p53 WT tumors. To test this hypothesis, we downloaded the somatic copy number alteration (SCNA) and patient survival data of 7.547 samples in 26 tumor types from cancer genome atlas (TCGA) [17] from UCSC Xena browser (https://xenabrowser.net/). We confirmed that in these tumor types p53 is mutated in more than 5% of the samples.
Our first goal was to study if the SCNA (both amplifications and deletions) in CDE+ genes is significantly lower specifically in p53 WT tumors compared to that of control genes, and not in p53 mutant tumors. As the control for our analysis, we used genes whose essentiality is not associated with p53 mutational status. To this end, we computed the copy number alterations (genomic instability (GI)) of a given geneset, which aims to quantify the relative amplification or deletion of genes in a tumor based on SCNA. Given si, the absolute of log ratio of SCNA of gene i in a sample relative to normal control, GI of the sample is given as in [31] :
where I is the indicator function, and i runs through the given subset of genes. We then checked whether the GI of CDE+ geneset is significantly lower than that of control non-CDE genes in p53 WT but not in p53 mutant tumors (using a Wilcoxon rank sum test).
Our second goal was to study if the magnitude of these SCNA levels of CDE+ genes is associated with enhanced patient survival, specifically in p53 WT tumors, as this would further testify that such amplification/deletion events reduce the fitness of these tumors. To this end, we used the following Cox proportional hazard model to identify the genes whose genomic alteration is associated with patient survival specifically in p53 WT tumor, while controlling for various confounding factors including the effect of cancer types, genome-wide genomic instability, sex, age, and race, tumor purity. We considered both amplification and deletion by taking the absolute value of SCNA levels, " ( ) = "0 ( ) ( , . 53 / , 2 / 3 + 5 + : + 553 53 + =, 2 + ==, ,
where g is an indicator variable over all possible combinations of patients' stratifications based on cancer-type, race, and sex. λg(t) is the hazard function (defined as the risk of death of patients per unit time) and λg0(t) is the baseline-hazard function at time t of the g th stratification. The model contains six covariates: (i) I(p53 + ,GI + ), an indicator variable that has value 1 if p53 is not mutated and the absolute value of SCNA level of the given gene i is greater than 50-percentile across all TCGA samples in the patient's tumor, and otherwise 0, (ii) purity, denoting tumor purity [32] , (iii) age, denoting patient's age, (iv) P53, denoting the p53 mutational status of the patient, (v) GIi, the absolute value of SCNA levels of the given gene i, and (vi) GGI, quantifying the genome-wide genomic instability (GGI) of the sample, as computed above. We tested the enrichment of CDE+ genes among the genes whose absolute SCNA levels are significantly associated with better patient survival specifically in p53 WT and not p53-mutated tumors using a hypergeometric test.
